Genome Opinion is at the forefront of precision medicine development targeting diseases driven by Clonal Hematopoiesis (CH). Utilizing our proprietary GENO-VERSE database, we employ a strategic methodology to enhance our research and development efforts. Our methodology encompasses:

• Identifying specific patient demographics for targeted therapeutic interventions.

• Discovering or acquiring tailored treatments for these groups.

• Expediting the clinical trial process via early local POC studies.